• Chugai and Biofourmis Partner to Develop an Objective Assessment of Pain Using Digital Technology

    • July 23, 2020
    • Posted By : admin
    • 0 Comment
    •   347 views

    Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) and Biofourmis, a Boston-based digital therapeutics company, announced that they have partnered to develop a digital solution for the objective assessment of pain associated with endometriosis.

    Pain is one of the main symptoms of endometriosis and therapeutically important. The severity of pain may vary from day to day, and it can be a major issue that affects patients’ quality of life. However, because pain can be a subjective symptom, patients often have difficulty quantifying their level of pain when communicating with healthcare professionals and family members.

    The partnership leverages Biofourmis’ Biovitals® platform to co-develop a novel digital technology for the objective assessment of pain using biosensors and artificial intelligence (AI)-based algorithms. The solution will be validated in a global, multi-center observational study enrolling more than 120 endometriosis patients.

    Biofourmis has demonstrated its ability to discover, develop and clinically validate multivariate digital biomarkers across multiple therapeutic areas. The digital solution for managing patients with endometriosis in an ambulatory setting will include a wearable, clinical-grade biosensor to capture physiology biomarkers and a patient-facing mobile app to monitor symptoms, with a gamification engine for patient engagement. The AI-based technology will provide a continuous quantification of pain by applying analytics to physiology biomarkers. The platform will also include a clinician-facing web dashboard for remote review and intervention.  

    0Shares
  347 views

You Might Also Like

No comments found

LEAVE COMMENT

Archive

Offers